A clear-eyed look at the evidence on prostate health, cardiovascular risk, and long-term monitoring
Safety concerns are the number one reason men hesitate to start TRT. We break down what two decades of clinical research actually says about long-term testosterone therapy.
"Is this safe?" It is the most common question physicians hear when discussing testosterone replacement therapy with patients. It is also the most important one. The honest answer, supported by an increasingly robust body of evidence, is: yes — when properly prescribed, monitored, and managed, TRT has a strong long-term safety profile.
That said, "safe" does not mean "without considerations." Understanding what the research actually shows — and what requires ongoing monitoring — is essential for anyone considering or currently on TRT.
TRT has been used clinically for over 70 years. The past two decades have produced increasingly rigorous long-term studies, including the landmark TRAVERSE trial (2023), which enrolled over 5,200 men with hypogonadism and cardiovascular risk factors and followed them for an average of ~33 months (nearly three years), finding no increase in major adverse cardiovascular events compared to placebo. For a deeper look at what the trial actually measured, see our testosterone and heart health post.
Long-term registry studies from Europe have followed men on TRT for up to 12 years, documenting sustained improvements in testosterone levels, body composition, sexual function, bone density, and quality of life — with no evidence of increased mortality.
Cardiovascular health. As discussed in detail in our article on testosterone and heart health, the current evidence does not support the idea that TRT increases cardiovascular risk in men with documented hypogonadism. The TRAVERSE trial specifically addressed this concern and found no increased risk of major adverse cardiovascular events.
Prostate health. For decades, the "androgen hypothesis" held that testosterone fueled prostate cancer growth. This theory has been substantially revised. Current evidence does not support the idea that TRT at physiologic levels increases prostate cancer risk. However, TRT is contraindicated in men with active prostate cancer, and PSA monitoring is standard practice on TRT.
Hematocrit. TRT stimulates red blood cell production. In some men, this causes hematocrit to rise above normal ranges — a condition called erythrocytosis. This is the most common clinically significant side effect of TRT and is managed through regular lab monitoring and dose adjustment when necessary.
Fertility. TRT suppresses the body's own testosterone production via the hypothalamic-pituitary-gonadal (HPG) axis, which also suppresses sperm production. Men who wish to preserve fertility should discuss this with their physician before starting TRT. Options including hCG co-administration can help maintain fertility on TRT.
NOT SURE WHERE TO START?
Take our 2-minute hormone & metabolism quiz to see exactly where you stand. Or skip ahead — a $49 lab panel gives you the numbers, a free hormone screen gives you a plan.
Liver health. Injectable and topical testosterone — the most commonly used forms — do not carry significant liver toxicity risk. Oral methyltestosterone (rarely used today) was associated with liver problems, but modern TRT protocols do not use this form.
Bone density. Long-term TRT consistently improves bone mineral density in men with hypogonadism, reducing fracture risk — a meaningful benefit for older men.
The safety of long-term TRT is not passive — it depends on active monitoring. A responsible TRT protocol includes:
| Lab Test | Frequency | Why It Matters |
|---|---|---|
| Total & free testosterone | Every 6–12 months | Ensure levels are in therapeutic range |
| Hematocrit / CBC | Every 6 months | Monitor for erythrocytosis |
| PSA | Annually (men 40+) | Prostate health screening |
| Estradiol | Every 6–12 months | Monitor estrogen conversion |
| Metabolic panel | Annually | Liver, kidney, glucose |
| Lipid panel | Annually | Cardiovascular risk factors |
At Primal Mountain Medical, lab monitoring is built into every protocol. We do not prescribe and disappear — we track your numbers and adjust your protocol as needed.
TRT is not appropriate for everyone. Contraindications include:
Twenty years of research — including the most rigorous randomized controlled trial ever conducted on TRT — supports the safety of testosterone replacement therapy in men with documented hypogonadism when properly monitored. The risks are real but manageable. The risks of leaving low testosterone untreated — metabolic disease, cardiovascular risk, bone loss, cognitive decline — are also real.
The goal is not to eliminate all risk. The goal is to make an informed decision with your physician, based on your individual health profile, with a monitoring plan in place.
Many men remain on TRT indefinitely. Long-term registry studies have followed men on TRT for up to 12 years with sustained benefits and no evidence of increased mortality. The key is ongoing monitoring.
Current evidence does not support the idea that TRT at physiologic levels causes prostate cancer. However, TRT is contraindicated in men with active prostate cancer, and PSA monitoring is standard practice.
Yes, you can stop TRT. However, your body's natural testosterone production will have been suppressed, so it may take weeks to months for levels to recover. Some men use a post-TRT protocol (hCG, clomiphene) to accelerate recovery.
Injectable and topical testosterone — the forms used in modern TRT protocols — do not carry significant liver toxicity risk. The liver concerns associated with testosterone were related to oral methyltestosterone, which is rarely used today.
Key labs include total and free testosterone, hematocrit, PSA, estradiol, metabolic panel, and lipid panel. Most physicians check these every 6 to 12 months depending on your protocol and individual risk factors.
Take our 2-minute hormone & metabolism quiz to see exactly where you stand — or jump straight to labs or a free screen with our team.